The Role of CD40 in Peripheral T Cell Tolerance and Immunity
Overview
Affiliations
CD40 and CD40 ligand (CD40L) have been implicated as important molecules for the transformation of nonactivated antigen-presenting cells (APC) into cells that are potent inducers of cytotoxic T lymphocyte (CTL) immunity. The onset of a successful immune response lies within the control of the CD4+ T helper cells which, after specific antigen recognition, can up-regulate CD40L and subsequently activate APC through CD40 signaling. Triggering of CD40 with antibodies in vivo can replace the need for CD40L-expressing CD4+ T helper cells for cross-priming of CTL. Blocking of CD40-CD40L interactions can also have profound effects on the generation of T cell immunity. Interestingly, differential involvement of CD40/CD40L in immune responses can be observed between various immunological sites in the body. In most sites of the periphery interruption of CD40-CD40L interactions can lead to the induction of T cell tolerance whereas in mucosal tissues this interruption can lead to abrogation of T cell tolerance. Furthermore, in vivo CD40 activation can convert specific T cell tolerance following peptide vaccination into efficient T cell priming. Thus intervention of CD40-CD40L interactions can result in enhancement or down-modulation of T cell reactivity and therefore modulation of these interactions may form the foundation of new treatment modalities directed against malignancies, allergies, organ rejections and autoimmunity.
CD27 microparticle interactions and immunoregulation of CD4 T lymphocytes.
Cagnet L, Neyrinck-Leglantier D, Tamagne M, Berradhia L, Khelfa M, Cleophax S Front Immunol. 2023; 14:1043255.
PMID: 36969173 PMC: 10034125. DOI: 10.3389/fimmu.2023.1043255.
Pan Q, Zhang Q, Chu J, Pais R, Liu S, He C Front Cell Infect Microbiol. 2018; 7:514.
PMID: 29326885 PMC: 5741698. DOI: 10.3389/fcimb.2017.00514.
The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.
Flynn N, Somasundaram R, Arnold K, Sims-Mourtada J Target Oncol. 2017; 12(2):139-152.
PMID: 28281220 DOI: 10.1007/s11523-017-0481-x.
Thompson E, Liang F, Lindgren G, Sandgren K, Quinn K, Darrah P J Immunol. 2015; 195(3):1015-24.
PMID: 26123354 PMC: 4506869. DOI: 10.4049/jimmunol.1500078.
Daedalic DNA vaccination against self antigens as a treatment for chronic kidney disease.
Wang Y, Zhou J, Wang Y, Watson D, Zhang G, Hu M Int J Clin Exp Pathol. 2013; 6(3):326-33.
PMID: 23412421 PMC: 3563188.